How to work with us
If you are looking for a Drug Development Expert who is fully aligned with your company’s vision, goals and objectives, the best solution is to enter into a midterm partnership with KarinJorga Life Science Consulting.
We offer two partnership variations that allow flexible and efficient collaboration towards common goals and tangible results.
Preferred Partner Package (P3)
We will define a number of consultancy days over a specified period of time (for example a total of 10 days over 6 months or a total of 20 days over 12 months) allowing us to hold respective capacity in our schedule so that you can count on our availability, when you need it.
This package enables us to collaborate with you on a variety of different projects and tasks in a very flexible way. The agreement is set up once and then the consultancy days can be scheduled according to your company’s needs. This solution is ideal for Venture firms who need support for Opportunity/Risk Assessments and Drug Development Expertise across their Portfolio Companies.
Project Package (P2)
This package specifies a number of consultancy days for dedicated project support (minimum 5 days per agreement, can be extended as needed) and an approximate time schedule to ensure that critical activities can be covered with the appropriate sense of urgency.
If you have an individual project that is in a critical phase and needs support to reach a specific goal, this may be the best solution for you. We put an agreement in place, define the deliverables and use the consultancy time in the most efficient way to reach the goal. This package works really well with Biotech teams that value continued and consistent support during the critical Early Development Phase.
You are not sure how much support you need or you have never worked with us and wish to experience the collaboration before you commit to a broader package? We also offer Single Packages (P1) covering clearly defined deliverables for a fixed fee and within a pre-defined timeframe.
Here are a few examples for possible Single Packages (P1)
Critical evaluation of all available pre-clinical and clinical data to assess the potential of the asset to reach Clinical Proof-of-Concept, registration and marketing. Identification of opportunities for Early Development acceleration and risk factors that need to be addressed to ensure best chances of development success.
Deliverables: Powerpoint presentation including data sources, methods, results and interpretation.
Integration of all available in vitro and in vivo pharmacology and toxicology data to determine a safe starting dose for the entry into human study and the maximum dose to be given to humans in early clinical trials. Prediction of therapeutic concentration range and potential therapeutic dose and dose regimen in the target patient population.
Deliverables: Powerpoint presentation including data sources, methods, results and interpretation (report for inclusion into IND package optional).
Evaluation of all available pre-clinical and clinical data and integration of knowledge in the context of publically available data (literature etc.) to assess whether or not a biomarker strategy and computer modeling and simulation can be used to accelerate the early development and increase the chances of development success.
Deliverables: Powerpoint presentation including data sources, methods, results and interpretation
Do you have data that seem inconsistent and difficult to explain? We evaluate the relevant pre-clinical and clinical data and integrate the information with knowledge from the literature to provide you with tangible hypothesis for the observed phenomenon.
Deliverables: Powerpoint presentation including data sources, methods, results and interpretation. Recommendation for focused experiments to test the hypothesis and assess the relevance for the further strategy.
If any of the solutions seems to fit the needs of your company or if you prefer a variation that is not listed above, just contact us.
We are just an email or a phone call away!